These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6601146)

  • 41. Interleukin 2.
    J Am Vet Med Assoc; 1983 Mar; 182(5):445-7. PubMed ID: 6601101
    [No Abstract]   [Full Text] [Related]  

  • 42. [Gingival responses following multiple challenges of bovine serum albumin (author's transl)].
    Yorifuji T
    Nihon Shishubyo Gakkai Kaishi; 1977 Dec; 19(4):275-88. PubMed ID: 288804
    [No Abstract]   [Full Text] [Related]  

  • 43. Response to comment on: Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity.
    Shi S; Liang Z; Sun B
    Vaccine; 2020 Mar; 38(13):2759. PubMed ID: 32145881
    [No Abstract]   [Full Text] [Related]  

  • 44. Lipopolysaccharides of oral anaerobes associated with chronic inflammation: chemical and immunomodulating properties.
    Hamada S; Takada H; Ogawa T; Fujiwara T; Mihara J
    Int Rev Immunol; 1990; 6(4):247-61. PubMed ID: 2102906
    [No Abstract]   [Full Text] [Related]  

  • 45. Interleukin 1: more than a mediator between leukocytes.
    Martin M; Resch K
    Trends Pharmacol Sci; 1988 May; 9(5):171-7. PubMed ID: 3073548
    [No Abstract]   [Full Text] [Related]  

  • 46. Program and abstracts for a symposium on the physiologic, metabolic, and immunologic actions of interleukin-1. Ann Arbor, June 4-6, 1985.
    J Leukoc Biol; 1985 Jun; 37(6):683-761. PubMed ID: 3872920
    [No Abstract]   [Full Text] [Related]  

  • 47. Gaston Ramon's Big Four.
    Chippaux JP
    Toxins (Basel); 2024 Jan; 16(1):. PubMed ID: 38251249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What Is IL-1 for? The Functions of Interleukin-1 Across Evolution.
    Boraschi D
    Front Immunol; 2022; 13():872155. PubMed ID: 35464444
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells.
    Ritvo PG; Klatzmann D
    Front Immunol; 2019; 10():250. PubMed ID: 30873158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploiting vita-PAMPs in vaccines.
    Blander JM; Barbet G
    Curr Opin Pharmacol; 2018 Aug; 41():128-136. PubMed ID: 29890457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triethylene glycol dimethacrylate: adjuvant properties and effect on cytokine production.
    Alizadehgharib S; Östberg AK; Dahlgren U
    Acta Biomater Odontol Scand; 2018; 4(1):1-9. PubMed ID: 29230430
    [No Abstract]   [Full Text] [Related]  

  • 52. From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology.
    Boraschi D; Italiani P
    Vaccines (Basel); 2015 Nov; 3(4):930-9. PubMed ID: 26556378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease.
    Bryant CE; Orr S; Ferguson B; Symmons MF; Boyle JP; Monie TP
    Pharmacol Rev; 2015; 67(2):462-504. PubMed ID: 25829385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The combination of early and rapid type I IFN, IL-1α, and IL-1β production are essential mediators of RNA-like adjuvant driven CD4+ Th1 responses.
    Madera RF; Wang JP; Libraty DH
    PLoS One; 2011; 6(12):e29412. PubMed ID: 22206014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants.
    Higgins SC; Mills KH
    Curr Infect Dis Rep; 2010 Jan; 12(1):4-12. PubMed ID: 21308494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
    Gwinn WM; Kirwan SM; Wang SH; Ashcraft KA; Sparks NL; Doil CR; Tlusty TG; Casey LS; Hollingshead SK; Briles DE; Dondero RS; Hickey AJ; Foster WM; Staats HF
    Vaccine; 2010 Oct; 28(42):6901-14. PubMed ID: 20723629
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells.
    Maue AC; Eaton SM; Lanthier PA; Sweet KB; Blumerman SL; Haynes L
    J Immunol; 2009 May; 182(10):6129-35. PubMed ID: 19414765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased production of pro-inflammatory cytokines and enhanced T cell responses after activation of human dendritic cells with IL-1 and CD40 ligand.
    Wesa A; Galy A
    BMC Immunol; 2002 Oct; 3():14. PubMed ID: 12385649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-1 beta, but not interleukin-1 alpha, is required for T-cell-dependent antibody production.
    Nakae S; Asano M; Horai R; Iwakura Y
    Immunology; 2001 Dec; 104(4):402-9. PubMed ID: 11899425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic use of interleukins: experimental results.
    Granstein RD; Tominaga A; Greene MI
    Surv Immunol Res; 1984; 3(2-3):127-34. PubMed ID: 6609400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.